Search results for " Control"

showing 10 items of 7691 documents

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer

2016

Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer.This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to f…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabAngiogenesisColorectal cancermedicine.medical_treatmentDrug Evaluation PreclinicalAngiogenesis InhibitorsDiseaseAntibodies Monoclonal HumanizedToxicologyRamucirumab03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicinemedicineAnimalsHumansRandomized Controlled Trials as TopicPharmacologyChemotherapyClinical Trials Phase I as TopicNeovascularization Pathologicbusiness.industryAntibodies MonoclonalCancerGeneral Medicinemedicine.diseaseVascular endothelial growth factorDisease Models Animal030104 developmental biologyClinical Trials Phase III as Topicchemistry030220 oncology & carcinogenesisColorectal Neoplasmsbusinessmedicine.drugExpert Opinion on Drug Metabolism & Toxicology
researchProduct

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

2017

Curative treatment of rectal cancer depends on an optimal surgical resection, with the addition of neoadjuvant radiotherapy (RT) with or without concomitant chemotherapy (ChT) in more advanced tumors. The role of adjuvant ChT is controversial and a more intensified neoadjuvant approach with the addition of ChT before or after RT, or even as single modality, is currently being explored in trials. A systematic review selecting randomised phase II and III trials on the role of ChT in localized rectal cancer was performed. Data show that neoadjuvant ChRT improves locoregional control in resected rectal cancer. Short-course RT (SCRT) could give similar outcomes to ChRT. The addition of oxaliplat…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAntineoplastic Agents03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicPreoperative chemoradiationInternal medicineMedicineCombined Modality TherapyHumansRadiology Nuclear Medicine and imagingRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicChemotherapybusiness.industryRectal NeoplasmsGeneral MedicineAdjuvant chemotherapy; Preoperative chemoradiation; Rectal cancermedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOxaliplatinAdjuvant chemotherapyRadiation therapy030104 developmental biologyOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisConcomitantRadiotherapy AdjuvantbusinessAdjuvantmedicine.drug
researchProduct

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer

2015

Abstract Aim A systematic review and meta-analysis from literature has been performed to assess the impact of targeted therapy in advanced pancreatic cancer. Methods By searching different literature databases and major cancer meetings proceedings, data from all randomized clinical trials designed to investigate molecular targeted agents in the treatment of advanced pancreatic cancer were collected. The time-frame between January 2007 and March 2015 was selected. Data on predefined end-points, including overall survival, progression-free survival in terms of Hazard Ratio and response-rate were extracted and analyzed by a random effects model. Pooled data analysis was performed according to …

0301 basic medicineOncologymedicine.medical_specialtyFunnel plotEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsBioinformaticslaw.inventionTargeted therapy03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseMeta-analysiAdvanced pancreatic cancerHepatologybusiness.industryHazard ratioGastroenterologyCancerPancreatic cancerPublication biasmedicine.diseasePancreatic NeoplasmsClinical trial030104 developmental biology030220 oncology & carcinogenesisMeta-analysisRandomized clinical trialbusinessSignal TransductionPathwayPancreatology
researchProduct

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

2018

Abstract Introduction Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation. In this scenario a new class of drugs, the PARP inhibitors (PARPis), produced a significant improvement in long-term disease control. In order to make an aggregate evaluation of the impact of these agents, we performed a systematic review and meta-analysis. Patients and Methods Clinical trials were selected by searching “Pubmed” database and abstracts from major cancer meetings. We considered the January 2008 - April 2018 time frame. Progression free surv…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOvarian cancerInternal medicinemedicineHumansMeta-analysiProgression-free survivalAdverse effectOvarian Neoplasmsbusiness.industryHazard ratioHematologyPrognosisClinical trial030104 developmental biologyPARP inhibitorOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCohortFemaleRandomized clinical trialMaintenance therapybusiness
researchProduct

Plasma Metabolites Associated with Coffee Consumption: A Metabolomic Approach within the PREDIMED Study

2019

Few studies have examined the association of a wide range of metabolites with total and subtypes of coffee consumption. The aim of this study was to investigate associations of plasma metabolites with total, caffeinated, and decaffeinated coffee consumption. We also assessed the ability of metabolites to discriminate between coffee consumption categories. This is a cross-sectional analysis of 1664 participants from the PREDIMED study. Metabolites were semiquantitatively profiled using a multiplatform approach. Consumption of total coffee, caffeinated coffee and decaffeinated coffee was assessed by using a validated food frequency questionnaire. We assessed associations between 387 metabolit…

0301 basic medicinePREDIMEDMalehumanosestudios de casos y controlescoffeeLibrary sciencelcsh:TX341-641030209 endocrinology & metabolismCoffee consumptionCoffeeArticleCohort Studies03 medical and health sciencesPlasma0302 clinical medicineCoffeescafeínaPolitical scienceCaffeinemetabolómicaHumansMetabolomicsestudios de cohortesmediana edadplasmaAgedanciano030109 nutrition & dieteticsNutrition and DieteticscaféMiddle AgedPredimedPredimedmetabolomicsCross-Sectional StudiesCase-Control StudiesChristian ministryFemalelcsh:Nutrition. Foods and food supplyestudios transversalesFood Science
researchProduct

Lack of NG2 exacerbates neurological outcome and modulates glial responses after traumatic brain injury

2015

Traumatic brain injury (TBI) is a major cause of death and disability. The underlying pathophysiology is characterized by secondary processes including neuronal death and gliosis. To elucidate the role of the NG2 proteoglycan we investigated the response of NG2-knockout mice (NG2-KO) to TBI. Seven days after TBI behavioral analysis, brain damage volumetry and assessment of blood brain barrier integrity demonstrated an exacerbated response of NG2-KO compared to wild-type (WT) mice. Reactive astrocytes and expression of the reactive astrocyte and neurotoxicity marker Lcn2 (Lipocalin-2) were increased in the perilesional brain tissue of NG2-KO mice. In addition, microglia/macrophages with acti…

0301 basic medicinePathologymedicine.medical_specialtyMicrogliaTraumatic brain injurybusiness.industryNeurotoxicityPoison controlBrain damagemedicine.diseaseBlood–brain barrier03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biologymedicine.anatomical_structurenervous systemNeurologyGliosisImmunologymedicineNeurogliamedicine.symptombusinessGlia
researchProduct

2017

Danger associated molecular patterns (DAMPs) are released by damaged cells and trigger neuroinflammation through activation of non-specific pattern recognition receptors (PRRs), e.g. Toll-like receptors (TLRs). Since the role of TLR 2 and 4 after traumatic brain injury (TBI) is still unclear, we examined the outcome and the expression of proinflammatory mediators after experimental TBI in Tlr2/4 / and wild-type (WT) mice. Tlr2/4 / and wild-type mice were subjected to controlled cortical injury and contusion volume and brain edema formation were assessed 24 h thereafter. Expression of inflammatory markers in brain tissue was measured by quantitative PCR 15 min, 3, 6, 12, and 24 h after contr…

0301 basic medicinePathologymedicine.medical_specialtyTraumatic brain injurybusiness.industryPoison controlmedicine.diseaseProinflammatory cytokine03 medical and health sciencesTLR2030104 developmental biology0302 clinical medicineImmune systemNeurologymedicineTumor necrosis factor alphaNeurology (clinical)Receptorbusiness030217 neurology & neurosurgeryNeuroinflammationFrontiers in Neurology
researchProduct

11 and 15-month-old infants do not compensate immediately for energy variation, and no further adjustment occurs 12 or 24 hours later

2021

International audience; Previously, we demonstrated that, in the short term, infants undercompensated for the energy from a preload given 25 min before an ad libitum meal. However, although not consistent, there is evidence in young children that caloric adjustment may occur over longer periods. We investigated the extent to which further energy adjustment occurs up to 24 h after a single meal preceded by preloads of varying energy density (ED) in infants that are 11 and 15 months old. Short-term caloric adjustment was measured in 11- and 15-month-old infants through a preload paradigm meal in the laboratory. To assess their caloric adjustment over longer periods (12 and 24 h), we used 24 h…

0301 basic medicinePediatricsmedicine.medical_specialtyAppetite controlCOMPXEnergy balanceAppetite030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineappetite controlpreload paradigmmedicineHumansChildMealsGeneral PsychologyMeal[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics030109 nutrition & dieteticsNutrition and DieteticsAppetite Regulationbusiness.industrydigestive oral and skin physiologyInfantCaloric theoryDiet RecordsPreloadChild Preschooldietary recordEnergy densityEnergy variationenergy intakecaloric adjustmentmedicine.symptomEnergy MetabolismbusinessWeight gain[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Effect of dietary interventions during weaning period on parental practice and lipoproteins and vitamin D status in two-year-old children

2016

ABSTRACT Objective: Evaluate if a two-day course for parents on nutrition and applied baby food preparation had an effect on child’s intake of home-made foods, lipid concentration, and vitamin D status. Design: Randomized controlled trial at age 6 months and follow-up at ages 15 and 24 months. Setting: Four health care clinics in Kristiansand, Norway. Subjects: Thirty-nine pairs of 6-month-old children and their parents in the intervention group and 20 pairs in the control group. Results: At age 15 months, the intervention group had lower intakes of ready-made porridge (2.0 vs. 5.8 servings per week (p < 0.05)), lower intake of canned baby food (2.9 vs. 6.3 servings per week (p < 0.05)) and…

0301 basic medicinePediatricsmedicine.medical_specialtyIntervention groupfeeding practicesArticlelaw.inventionBaby food03 medical and health sciencesDietary interventionschemistry.chemical_compoundRandomized controlled triallawCooking classesVitamin D and neurologyMedicineWeaningtoddlers030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryCholesterolCanned baby foodPublic Health Environmental and Occupational HealthlipoproteinschemistrybusinessdietFood Science
researchProduct